JP7572353B2 - トリアゾロ－ピリミジン化合物およびそれらの使用 - Google Patents

トリアゾロ－ピリミジン化合物およびそれらの使用 Download PDF

Info

Publication number
JP7572353B2
JP7572353B2 JP2021513827A JP2021513827A JP7572353B2 JP 7572353 B2 JP7572353 B2 JP 7572353B2 JP 2021513827 A JP2021513827 A JP 2021513827A JP 2021513827 A JP2021513827 A JP 2021513827A JP 7572353 B2 JP7572353 B2 JP 7572353B2
Authority
JP
Japan
Prior art keywords
pyrimidin
triazolo
methyl
amine
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021513827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500402A (ja
JP2022500402A5 (https=
JPWO2020052631A5 (https=
Inventor
ゼン，チンベイ
チ，チャンヘ
ツイ，ホンチュン
ヤン，チェンファン
チャン，シャオリン
Original Assignee
ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド filed Critical ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド
Publication of JP2022500402A publication Critical patent/JP2022500402A/ja
Publication of JP2022500402A5 publication Critical patent/JP2022500402A5/ja
Publication of JPWO2020052631A5 publication Critical patent/JPWO2020052631A5/ja
Priority to JP2024096058A priority Critical patent/JP2024123079A/ja
Application granted granted Critical
Publication of JP7572353B2 publication Critical patent/JP7572353B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021513827A 2018-09-12 2019-09-12 トリアゾロ－ピリミジン化合物およびそれらの使用 Active JP7572353B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024096058A JP2024123079A (ja) 2018-09-12 2024-06-13 トリアゾロ－ピリミジン化合物およびそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/105220 2018-09-12
CN2018105220 2018-09-12
PCT/CN2019/105591 WO2020052631A1 (en) 2018-09-12 2019-09-12 Triazolo-pyrimidine compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024096058A Division JP2024123079A (ja) 2018-09-12 2024-06-13 トリアゾロ－ピリミジン化合物およびそれらの使用

Publications (4)

Publication Number Publication Date
JP2022500402A JP2022500402A (ja) 2022-01-04
JP2022500402A5 JP2022500402A5 (https=) 2022-09-05
JPWO2020052631A5 JPWO2020052631A5 (https=) 2022-09-05
JP7572353B2 true JP7572353B2 (ja) 2024-10-23

Family

ID=69778192

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021513827A Active JP7572353B2 (ja) 2018-09-12 2019-09-12 トリアゾロ－ピリミジン化合物およびそれらの使用
JP2024096058A Pending JP2024123079A (ja) 2018-09-12 2024-06-13 トリアゾロ－ピリミジン化合物およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024096058A Pending JP2024123079A (ja) 2018-09-12 2024-06-13 トリアゾロ－ピリミジン化合物およびそれらの使用

Country Status (12)

Country Link
US (2) US10858365B2 (https=)
EP (1) EP3849983A4 (https=)
JP (2) JP7572353B2 (https=)
KR (1) KR102841843B1 (https=)
CN (3) CN111635408B (https=)
AR (1) AR116315A1 (https=)
AU (1) AU2019340767B9 (https=)
BR (1) BR112021004774A2 (https=)
CA (1) CA3111869A1 (https=)
MX (1) MX2021002998A (https=)
TW (1) TWI820209B (https=)
WO (1) WO2020052631A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024123079A (ja) * 2018-09-12 2024-09-10 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド トリアゾロ－ピリミジン化合物およびそれらの使用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11066410B2 (en) * 2017-03-24 2021-07-20 3100 Central Expressway Llc Fused triazolo-pyrimidine compounds having useful pharmaceutical application
WO2019018584A1 (en) 2017-07-18 2019-01-24 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
GEP20237548B (en) 2018-07-05 2023-10-10 Incyte Corp Fused pyrazine derivatives as a2a /a2b inhibitors
EP3911324A4 (en) 2019-01-18 2022-08-17 Nuvation Bio Inc. 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
EP3911323A4 (en) 2019-01-18 2022-11-16 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US20210061809A1 (en) * 2019-08-26 2021-03-04 Incyte Corporation Triazolopyrimidines as a2a / a2b inhibitors
WO2021156439A1 (en) 2020-02-06 2021-08-12 Astrazeneca Ab Triazole compounds as adenosine receptor antagonists
CN120022278A (zh) * 2023-11-22 2025-05-23 英诺湖医药(杭州)有限公司 用于治疗癌症的化合物
CN117865963B (zh) * 2023-12-15 2026-02-24 上海凌凯科技股份有限公司 一种嘧啶酮衍生物的合成方法及嘧啶酮衍生物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079204A1 (en) 2001-03-28 2002-10-10 Kyowa Hakko Kogyo Co., Ltd. 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine derivative
WO2004029056A1 (ja) 2002-09-24 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. [１，２，４]トリアゾロ[１，５−ｃ]ピリミジン誘導体
JP2005511698A (ja) 2001-11-30 2005-04-28 シェーリング　コーポレイション アデノシンＡ２ａレセプターアンタゴニスト
WO2018184590A1 (zh) 2017-04-07 2018-10-11 南京明德新药研发股份有限公司 作为A 2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
WO2019206336A1 (zh) 2018-04-28 2019-10-31 南京明德新药研发有限公司 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4195729B2 (ja) * 1997-03-24 2008-12-10 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
CN110214012B (zh) * 2017-01-20 2023-05-09 艾库斯生物科学有限公司 用于治疗癌症相关疾病的唑嘧啶
CN109963854B (zh) * 2017-03-16 2022-04-12 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
CN109535161B (zh) * 2017-09-22 2021-09-03 江苏恒瑞医药股份有限公司 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用
AR116315A1 (es) * 2018-09-12 2021-04-21 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos de triazolo-pirimidina y usos de los mismos

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079204A1 (en) 2001-03-28 2002-10-10 Kyowa Hakko Kogyo Co., Ltd. 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine derivative
JP2005511698A (ja) 2001-11-30 2005-04-28 シェーリング　コーポレイション アデノシンＡ２ａレセプターアンタゴニスト
WO2004029056A1 (ja) 2002-09-24 2004-04-08 Kyowa Hakko Kogyo Co., Ltd. [１，２，４]トリアゾロ[１，５−ｃ]ピリミジン誘導体
WO2018184590A1 (zh) 2017-04-07 2018-10-11 南京明德新药研发股份有限公司 作为A 2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
WO2019206336A1 (zh) 2018-04-28 2019-10-31 南京明德新药研发有限公司 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Saudi Chem. Soc.，2003年，7(2)，207-212

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024123079A (ja) * 2018-09-12 2024-09-10 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド トリアゾロ－ピリミジン化合物およびそれらの使用

Also Published As

Publication number Publication date
BR112021004774A2 (pt) 2021-08-03
TW202024089A (zh) 2020-07-01
JP2022500402A (ja) 2022-01-04
CN111635408B (zh) 2022-07-22
MX2021002998A (es) 2021-05-14
CN111635408A (zh) 2020-09-08
US11629147B2 (en) 2023-04-18
TWI820209B (zh) 2023-11-01
CN111601809A (zh) 2020-08-28
AU2019340767B9 (en) 2024-12-05
CN112279852A (zh) 2021-01-29
KR20210075996A (ko) 2021-06-23
WO2020052631A1 (en) 2020-03-19
US20210009600A1 (en) 2021-01-14
US10858365B2 (en) 2020-12-08
JP2024123079A (ja) 2024-09-10
AU2019340767A1 (en) 2021-04-08
EP3849983A1 (en) 2021-07-21
CA3111869A1 (en) 2020-03-19
AU2019340767B2 (en) 2024-11-14
AR116315A1 (es) 2021-04-21
KR102841843B1 (ko) 2025-08-01
US20200331918A1 (en) 2020-10-22
CN112279852B (zh) 2023-01-17
EP3849983A4 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
JP7572353B2 (ja) トリアゾロ－ピリミジン化合物およびそれらの使用
JP7540996B2 (ja) ピラジン化合物およびその使用
KR20200131246A (ko) 키나제 억제제로서의 헤테로시클릭 화합물
AU2023202886A1 (en) Adenosine receptor antagonist compounds
CN115181092B (zh) 吡嗪化合物和其用途
RU2802866C9 (ru) Соединения триазоло-пиримидина и их применение
RU2802866C2 (ru) Соединения триазоло-пиримидина и их применение
HK40045058B (en) Triazolo-pyrimidine compounds and uses thereof
HK40045058A (en) Triazolo-pyrimidine compounds and uses thereof
HK40027808B (en) Triazolo-pyrimidine compounds and uses thereof
HK40027808A (en) Triazolo-pyrimidine compounds and uses thereof
RU2809631C2 (ru) Пиразиновые соединения и их применения
HK40026664A (en) Triazolo-pyrimidine compounds and uses thereof
EA042905B1 (ru) Ингибиторы клеточных метаболических процессов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220826

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240613

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240722

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241010

R150 Certificate of patent or registration of utility model

Ref document number: 7572353

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150